|
|
|
|
|
|
|
Myovant Sciences Ltd (MYOV)
|
|
21.1 0.37 (1.78%)
|
04-20 16:01
|
|
Open:
|
20.87
|
Pre. Close:
|
20.73
|
|
High:
|
21.29
|
Low:
|
20.59
|
|
Volume:
|
61,028
|
Market Cap:
|
1310M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
21.309 - 21.459
|
21.459 - 21.575
|
|
Low:
|
20.312 - 20.47
|
20.47 - 20.592
|
|
Close:
|
20.893 - 21.138
|
21.138 - 21.329
|
|
|
|
Technical analysis (as of: 2018-04-20 4:32:01 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a SELL today, upgraded from strong sell. But this stock still is very strong for short side. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell as long as the BUY warning is not issued.
|
|
Target:
|
Six months: 28.19 One year: 32.93
|
|
Support:
|
Support1: 20.35 Support2: 18.01
|
|
Resistance:
|
Resistance1:
24.14 Resistance2: 28.19
|
|
Pivot:
|
21.34 
|
|
Moving Averages:
|
MA(5): 21.61 MA(20): 21.07
MA(100): 15.45 MA(250): 13.87
|
|
MACD:
|
MACD(12,26):
1.01 Signal(12,26,9): 1.22
|
|
%K %D:
|
%K(14,3): 54.20 %D(3): 59.02
|
|
RSI:
|
RSI(14): 56.30
|
|
52-Week:
|
High: 24.137
Low: 9.92 Change(%): 72.4
|
|
Average Vol(K):
|
3-Month: 9485
10-Days 19850
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.MYOV has closed above bottom band by 41.0%. Bollinger Bands are 7.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-04-20T08:00:00-04:00
Myovant Sciences and PERIOD. Inc. Launch Partnership Focused on Empowering Women to Elevate the Conversation Around Period Health
2018-04-09T03:46:20-04:00
BioSci Research On Myovant Sciences (Part I): Is This A Big Winner In The Making?
2018-04-06T12:33:34-04:00
BioSci Rounds Report: Intercept Is Making A Comeback While Improving FDA Policy Can Help Geron
2018-04-04T08:00:00-04:00
Your Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path Results
2018-04-03T09:25:48-04:00
Myovant announces Private Placement and At-the-Market Offering Program
2018-03-27T12:59:05-04:00
Midday Gainers / Losers (03/27/2018)
2018-03-06T17:00:00-05:00
Myovant Sciences to Present at Upcoming Investor Conferences
2018-02-22T11:53:40-05:00
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2017 Update
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
NA
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
NA
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
